• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

极高危和非极高危动脉粥样硬化性心血管疾病患者的特征和急性心血管事件发生率。

Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease.

机构信息

Ahmanson-UCLA Cardiomyopathy Center, David Geffen School of Medicine, University of California, Los Angeles, California, USA.

Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri, USA.

出版信息

Clin Cardiol. 2021 Oct;44(10):1457-1466. doi: 10.1002/clc.23706. Epub 2021 Aug 5.

DOI:10.1002/clc.23706
PMID:34351003
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8495090/
Abstract

BACKGROUND

The risk for subsequent major cardiovascular (CV) events among patients with very high-risk (VHR) atherosclerotic CV disease (ASCVD) remains to be fully elucidated.

HYPOTHESIS

We assessed the characteristics and major CV event rates of patients with VHR versus non-VHR ASCVD in a real-world setting in the United States (US), hypothesizing that patients with VHR ASCVD would have higher CV event rates.

METHODS

This was a retrospective cohort study conducted from January 01, 2011, to June 30, 2018, in the US using the Prognos LDL-C database linked to the IQVIA PharMetrics Plus® database supplemented with the IQVIA prescription claims (Dx/LRx) databases. Patients were ≥18 years old and had  ≥2 non-ancillary medical claims in the linked databases at least 30 days apart. The study was conducted in 2 stages: (1) identification of patients with ASCVD who met the definition of VHR ASCVD and a matched cohort of non-VHR ASCVD patients using the incidence density sampling (IDS) approach; (2) estimation of the occurrence of major CV events.

RESULTS

Among patients with ≥1 major ASCVD event (N=147,679), most qualified as VHR ASCVD (79.5%). There were 115,460 patients each in IDS-matched VHR and non-VHR ASCVD cohorts. The composite myocardial infarction/ischemic stroke event rates in the VHR and non-VHR ASCVD cohorts were 8.04 (95% confidence interval [95% CI]: 7.87-8.22) and 0.82 (95% CI: 0.77-0.88) events per 100 patient-years, respectively, during the 1-year post-index period.

CONCLUSIONS

Most patients with ≥1 previous major ASCVD event treated in real-world US clinical practice qualified as VHR ASCVD. Patients with VHR ASCVD had much higher rates of major CV events versus non-VHR ASCVD patients.

摘要

背景

极高危(VHR)动脉粥样硬化性心血管疾病(ASCVD)患者发生后续主要心血管(CV)事件的风险仍有待充分阐明。

假设

我们在美国(US)的真实环境中评估了 VHR 与非 VHR ASCVD 患者的特征和主要 CV 事件发生率,假设 VHR ASCVD 患者的 CV 事件发生率更高。

方法

这是一项回顾性队列研究,于 2011 年 1 月 1 日至 2018 年 6 月 30 日在美国进行,使用 Prognos LDL-C 数据库与 IQVIA PharMetrics Plus®数据库链接,并补充 IQVIA 处方(Dx/LRx)数据库。患者年龄≥18 岁,在链接数据库中至少有 30 天的≥2 次非辅助医疗索赔。该研究分两个阶段进行:(1)使用发生率密度抽样(IDS)方法确定符合 VHR ASCVD 定义的 ASCVD 患者和非 VHR ASCVD 患者的匹配队列;(2)估计主要 CV 事件的发生。

结果

在≥1 次主要 ASCVD 事件的患者中(N=147679),大多数患者符合 VHR ASCVD 标准(79.5%)。IDS 匹配的 VHR 和非 VHR ASCVD 队列中各有 115460 名患者。VHR 和非 VHR ASCVD 队列中复合心肌梗死/缺血性卒中事件发生率在索引后 1 年内分别为 8.04(95%置信区间[95%CI]:7.87-8.22)和 0.82(95%CI:0.77-0.88)/100 患者年。

结论

在真实世界的美国临床实践中,大多数有≥1 次既往主要 ASCVD 事件的患者符合 VHR ASCVD 标准。VHR ASCVD 患者的主要 CV 事件发生率明显高于非 VHR ASCVD 患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4fc/8495090/369a19310220/CLC-44-1457-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4fc/8495090/fbcdf8a4ff0c/CLC-44-1457-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4fc/8495090/369a19310220/CLC-44-1457-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4fc/8495090/fbcdf8a4ff0c/CLC-44-1457-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4fc/8495090/369a19310220/CLC-44-1457-g002.jpg

相似文献

1
Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease.极高危和非极高危动脉粥样硬化性心血管疾病患者的特征和急性心血管事件发生率。
Clin Cardiol. 2021 Oct;44(10):1457-1466. doi: 10.1002/clc.23706. Epub 2021 Aug 5.
2
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.使用新的美国心脏病学会/美国心脏协会胆固醇管理指南进行风险分类及其与急性冠状动脉综合征后依洛尤单抗治疗的关系。
Circulation. 2019 Nov 5;140(19):1578-1589. doi: 10.1161/CIRCULATIONAHA.119.042551. Epub 2019 Sep 2.
3
Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States.在美国患有主要动脉粥样硬化性心血管疾病事件的真实患者群体中,降脂治疗利用率、低密度脂蛋白胆固醇(LDL-C)水平以及回顾性符合美国心脏病学会(ACC)/美国心脏协会(AHA)极高风险标准的比例的地理差异。
Am J Prev Cardiol. 2021 Mar 30;6:100177. doi: 10.1016/j.ajpc.2021.100177. eCollection 2021 Jun.
4
Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data.高动脉粥样硬化性心血管疾病风险人群中的心血管事件发生率:来自瑞典基于人群的登记数据的估计。
Eur Heart J Qual Care Clin Outcomes. 2019 Jul 1;5(3):225-232. doi: 10.1093/ehjqcco/qcy058.
5
Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real-world evidence study.加拿大艾伯塔省动脉粥样硬化性心血管疾病的流行情况及随后发生的主要不良心血管事件:一项真实世界证据研究。
Clin Cardiol. 2021 Nov;44(11):1613-1620. doi: 10.1002/clc.23732. Epub 2021 Sep 29.
6
Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States.脂蛋白(a)对动脉粥样硬化性心血管疾病患者的负担:来自美国的回顾性分析。
J Manag Care Spec Pharm. 2023 May;29(5):519-529. doi: 10.18553/jmcp.2023.29.5.519.
7
Evaluating a Simple Approach to Identify Adults Meeting the 2018 AHA/ACC Cholesterol Guideline Definition of Very High Risk for Atherosclerotic Cardiovascular Disease.评估一种简单方法识别符合 2018 年美国心脏协会/美国心脏病学会胆固醇指南定义的动脉粥样硬化性心血管疾病极高危人群。
Cardiovasc Drugs Ther. 2022 Jun;36(3):475-481. doi: 10.1007/s10557-021-07167-1. Epub 2021 Mar 4.
8
High-Risk Atherosclerotic Cardiovascular Disease in a Real-World Employed Japanese Population: Prevalence, Cardiovascular Event Rates, and Costs.日本在职人群中的高危动脉粥样硬化性心血管疾病:患病率、心血管事件发生率及成本
J Atheroscler Thromb. 2015;22(12):1287-304. doi: 10.5551/jat.28852. Epub 2015 Aug 18.
9
Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.在美国医保支付方背景下,高危二级预防人群中心血管疾病的估计负担以及依洛尤单抗的基于价值的价格范围。
J Med Econ. 2017 Jun;20(6):555-564. doi: 10.1080/13696998.2017.1284078. Epub 2017 Jan 25.
10
Ischemic Event Rates in Very-High-Risk Adults.极高危成年人中的缺血性事件发生率。
J Am Coll Cardiol. 2019 Nov 19;74(20):2496-2507. doi: 10.1016/j.jacc.2019.09.025.

引用本文的文献

1
IL-6 and Cardiovascular Risk: A Narrative Review.白细胞介素-6 与心血管风险:一篇叙述性综述。
Curr Atheroscler Rep. 2024 Nov 26;27(1):12. doi: 10.1007/s11883-024-01259-7.
2
Prevalence of Tendon Rupture and Tendinopathies Among Patients with Atherosclerotic Cardiovascular Disease Derived From United States Administrative Claims Data.基于美国行政索赔数据的动脉粥样硬化性心血管疾病患者肌腱断裂和肌腱病的患病率
Cardiol Ther. 2024 Sep;13(3):575-591. doi: 10.1007/s40119-024-00374-5. Epub 2024 Jul 14.
3
The Role of Endothelial Progenitor Cells in Atherosclerosis and Impact of Anti-Lipemic Treatments on Endothelial Repair.

本文引用的文献

1
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.依洛尤单抗对近期心肌梗死患者心血管结局的疗效: FOURIER 试验的预先设定的次要分析。
JAMA Cardiol. 2020 Aug 1;5(8):952-957. doi: 10.1001/jamacardio.2020.0882.
2
Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified.接受前蛋白转化酶枯草溶菌素9型抑制剂治疗的患者以及当前降脂治疗方案已更改的患者的人口统计学和临床特征。
Ther Clin Risk Manag. 2019 Nov 13;15:1325-1332. doi: 10.2147/TCRM.S216606. eCollection 2019.
3
内皮祖细胞在动脉粥样硬化中的作用及抗脂治疗对内皮修复的影响。
Int J Mol Sci. 2022 Feb 28;23(5):2663. doi: 10.3390/ijms23052663.
Ischemic Event Rates in Very-High-Risk Adults.
极高危成年人中的缺血性事件发生率。
J Am Coll Cardiol. 2019 Nov 19;74(20):2496-2507. doi: 10.1016/j.jacc.2019.09.025.
4
Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.改善对低密度脂蛋白胆固醇和血脂异常管理的认识(GOULD):美国高心血管风险患者注册研究的方法和基线数据。
Am Heart J. 2020 Jan;219:70-77. doi: 10.1016/j.ahj.2019.10.014. Epub 2019 Oct 31.
5
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.使用新的美国心脏病学会/美国心脏协会胆固醇管理指南进行风险分类及其与急性冠状动脉综合征后依洛尤单抗治疗的关系。
Circulation. 2019 Nov 5;140(19):1578-1589. doi: 10.1161/CIRCULATIONAHA.119.042551. Epub 2019 Sep 2.
6
Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease.依洛尤单抗治疗超高危动脉粥样硬化性心血管疾病患者的成本效果更新分析。
JAMA Cardiol. 2019 Jul 1;4(7):691-695. doi: 10.1001/jamacardio.2019.1647.
7
Trends in low-density lipoprotein-cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines.2012年至2017年间低密度脂蛋白胆固醇血液值的趋势表明,近期2013年治疗指南的采用情况不佳。
Clin Cardiol. 2019 Jan;42(1):101-110. doi: 10.1002/clc.23115. Epub 2018 Nov 30.
8
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2018年美国心脏协会/美国心脏病学会/美国心血管和肺康复协会/美国医师助理学会/美国心脏协会/美国预防医学学会/美国糖尿病协会/美国老年医学会/美国药剂师协会/美国临床内分泌医师协会/美国国家脂质协会/美国初级保健医师学会血胆固醇管理指南:执行摘要:美国心脏病学会/美国心脏协会临床实践指南工作组报告
J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002. Epub 2018 Nov 10.
9
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.依洛尤单抗与急性冠脉综合征后的心血管结局。
N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.
10
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.依冠状动脉疾病严重程度和范围评估依洛尤单抗的临床获益:FOURIER 分析。
Circulation. 2018 Aug 21;138(8):756-766. doi: 10.1161/CIRCULATIONAHA.118.034309.